News

Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.

Anemia could be a reliable sign of all-cause mortality in patients with heart failure.

In this analysis, the investigators sought to assess the efficacy and safety of risankizumab compared to placebo for patients with palmoplantar psoriasis.

A study found that migraine-related disability worsens health-related quality of life, with gender-specific differences, particularly affecting women with mild disability.

Linaclotide was safe and effective for patients with chronic constipation and IBS with constipation who switched after non-response to magnesium oxide.

These data resulted from comparisons of the time to onset of action among various available systemic medications for those with plaque psoriasis.

A systematic review found cognitive impairment a defining characteristic of SCA, with a notable impact on individuals of all ages.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.

Stephanie Christenson, MD, discusses the impact of recent regulatory approvals and pipeline movement for chronic obstructive pulmonary disease.

The ustekinumab biosimilar will be available in early 2025, with indications to treat psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

Phase 3 data found 66.5% of people with migraine attacks treated with STS101 had headache pain relief two hours after the dose.

In focus groups, patients indicated symptom bothersomeness and life interference should be included in clinical evaluation for disorders of gut-brain interaction.

Linda Gillam, MD, MPH, discusses updates in the management of aortic stenosis, with a focus on use of TAVR.

This analysis indicates that patients with a history of a first melanoma are at risk for subsequent development of melanoma regardless of their race or their ethnicity.

A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.

These data highlight barriers to pediatric treatments for eczema, providing potential strategies for caregivers and patients for adherence improvement.

A meta-analysis revealed taking pregabalin with supplement vitamin D reduced migraine frequency in children by 88%

The sNDA submission to the FDA included a Priority Review Voucher, which commits the regulatory agency to an accelerated review timeline.

The anti-TFPI significantly reduced ABR compared to routine prophylaxis treatment in the phase 3 BASIS trial.

Linda Gillam, MD, MPH, discusses the idea that the cardiology community may. be overtreating aortic stenosis.

This research letter suggests that direct GOC may be considered efficacious for pediatric patients reporting non-severe symptoms which are skin-limited during a macrolide treatment.

New phase 2b data highlight denifanstat’s impact on histological features of MASH, meeting both fibrosis improvement and MASH resolution primary endpoints.

Factors, including older age at onset and longer length of stay, may predict longevity for schizophrenia in psychiatric long-term care settings.

A study finds CGRP monoclonal antibodies are not clinically superior to topiramate or Botox in treating chronic migraines, raising cost-effectiveness concerns.

Findings support the feasibility and clinical performance of Xpert HCV, the first FDA-approved point-of-care test for diagnosing HCV, in a nonclinical justice setting.

Second-generation long-acting injectables were particularly underutilized, and especially among older patients.

While this analysis found social anhedonia may be a potential intervention for some, nonsocial cognition may have a significant role in social disconnection for those with schizophrenia.

A short-term rise in air pollution levels between neighboring days was significantly linked to an increased risk of schizophrenia hospitalizations in China.